Mesalazine granule formulation improves clinical data in Crohn’s disease compared with tablet formulation

• Material Type: 博士論文
• ISSN: 2045-2322
• Title: Mesalazine granule formulation improves clinical data in Crohn’s disease compared with tablet formulation
• Volume: 10
• Author/Editor: 田村, 智
• Author Heading: 田村, 智
• Publication, Distribution, etc.: Springer Nature
• Publication Date: 2020-12-07
• Publication Date (W3CDTF): 2020-12-07
• Alternative Title: メサラジン顆粒剤は錠剤と比較してクローン病の臨床データを改善させる
• Periodical title: Scientific Reports
• Degree grantor/type: 浜松医科大学
• Date Granted: 2021-03-16
• Date Granted (W3CDTF): 2021-03-16
• Dissertation Number: 甲第862号
• Degree Type: 博士（医学）
• Conferring No. (Dissertation): 甲第862号
• Text Language Code: eng
• Target Audience: 一般
• Note (General): doctoral; 医学系研究科; The efficacy of sustained-release preparations of mesalazine as a remission maintenance treatment for Crohn’s disease remains to be established. We aimed to examine the changes in compliance rate and clinical data 2 years after switching from mesalazine tablet to granule formulation at our facility among patients with Crohn’s disease in remission. We investigated the rate of continuous treatment of mesalazine granules and examined the changes in Crohn’s Disease Activity Index (CDAI) and serum C-reactive protein (CRP), albumin, and hemoglobin (Hb) levels 2 years after the switch. Compliance rate (continuous treatment vs. additional treatment) and continuous treatment rate [good (rate of ≥70%) vs. poor (rate<70%)] were investigated. Of 46 patients, 12 (27.3%) received additional treatment and 32 (72.7%) did not require additional treatment in 2 years. No significant change in CDAI after switching to granule modification was noted in 32 patients in the continuous treatment group. Nevertheless, clinical remission was maintained for 2 years, and serum CRP levels decreased significantly (P=0.023) and Hb levels increased significantly (P=0.002). No change in the compliance rate was found. Our results suggest that mesalazine granule formulation may have a remission maintenance effect that is superior to that of mesalazine tablets.
• DOI: info:doi/10.1038/s41598-020-78603-9; https://doi.org/info:doi/10.1038/s41598-020-78603-9
• Persistent ID (NDL): info:ndljp/pid/11720308; https://dl.ndl.go.jp/pid/11720308
• Collection: 障害者向け資料
• Collection (Materials For Handicapped People:1): テキストデータ
• Collection (particular): 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文; https://dl.ndl.go.jp/collections/A00014
• Acquisition Basis: 博士論文（自動収集）
• Date Accepted (W3CDTF): 2021-09-06T03:11:00+09:00
• Date Created (W3CDTF): 2021-07-20
• Format (IMT): application/pdf
• Access Restrictions: 国立国会図書館内限定公開
• Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
• Availability of remote photoduplication service: 可
• Periodical Title (URI): http://hdl.handle.net/10271/00003871; https://hama-med.repo.nii.ac.jp/records/3745
• Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp

Table of Contents

2023-09-02 再収集

2023-10-11 再収集

2023-12-15 再収集